What is Tirzepatide?
Tirzepatide is a first-in-class, once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved for treating type 2 diabetes mellitus and obesity. 1, 2
Mechanism of Action
Tirzepatide works through dual receptor activation that produces complementary metabolic effects 2, 3:
- Increases insulin secretion in a glucose-dependent manner
- Decreases glucagon levels, reducing hepatic glucose production
- Slows gastric emptying, prolonging satiety
- Acts centrally to reduce appetite and food intake
- Modulates gut microbiota, increasing Bacteroidetes and decreasing Firmicutes while enhancing intestinal barrier integrity
Clinical Indications
Type 2 Diabetes Mellitus
Tirzepatide produces substantial glycemic improvements across the SURPASS trial program, with HbA1c reductions of -1.87% to -2.58% depending on dose (5 mg, 10 mg, or 15 mg weekly) 4. These reductions exceed those achieved with GLP-1 receptor agonists like semaglutide or dulaglutide 5, 4.
Obesity
In the SURMOUNT trials, tirzepatide demonstrated marked weight reduction of -6.2 to -12.9 kg, with the magnitude of weight loss exceeding that of GLP-1 receptor agonists 1, 4. For adults with obesity, the BMJ 2025 guideline suggests using tirzepatide (weak recommendation), though clinicians must weigh the larger weight loss benefits against the higher certainty of cardiovascular and kidney benefits offered by GLP-1 receptor agonists 1.
Multi-Organ Effects
Tirzepatide functions as a multi-organ integrator with effects beyond glucose control 2, 3:
- Cardiovascular: Improves lipid profiles, reduces blood pressure, and decreases inflammatory biomarkers
- Hepatic: Reduces hepatic steatosis in MASLD
- Renal: Shows favorable effects on kidney-related endpoints in exploratory analyses
- Respiratory: Improves obstructive sleep apnea severity in adults with obesity
- Heart Failure: SUMMIT trial demonstrates reductions in worsening heart failure events and improvements in health status specifically in obesity-related HFpEF 3
Cardiovascular Safety and Outcomes
The SURPASS-CVOT trial established cardiovascular safety by demonstrating noninferiority versus dulaglutide for 3-point major adverse cardiovascular events in patients with type 2 diabetes and established atherosclerotic cardiovascular disease 3. However, the certainty of cardiovascular and kidney benefits remains lower compared to GLP-1 receptor agonists 1.
Important Clinical Considerations
Combination Therapy Rules
- Should NOT be combined with GLP-1 receptor agonists (overlapping mechanism) 1
- Can be combined with SGLT-2 inhibitors and finerenone 1
- In higher-risk patients, tirzepatide should generally not replace medications proven effective for cardiovascular and kidney complications 1
When Choosing Between Tirzepatide and GLP-1 Receptor Agonists
For lower-risk patients with obesity: Most will choose tirzepatide given superior weight loss effects 1
For moderate-to-higher risk patients: The decision requires nuance—balance tirzepatide's larger weight loss (moderate certainty) against GLP-1 receptor agonists' higher certainty cardiovascular and kidney benefits 1. If replacing a GLP-1 receptor agonist with tirzepatide in higher-risk patients, initiation or continuation of an SGLT-2 inhibitor is indicated 1.
Adverse Effects
The most common adverse events are mild gastrointestinal symptoms (nausea, vomiting, diarrhea), occurring at rates comparable to GLP-1 receptor agonists 4. Severe gastrointestinal events occur with moderate certainty evidence 1.
Dermatologic effects include 6:
- Injection-site reactions (slightly more frequent than semaglutide)
- Hypersensitivity reactions
- Facial volume loss from rapid weight reduction (cosmetic consideration)
Serious hypoglycemia risk is not increased when used appropriately 4.
Dosing
Administered as a once-weekly subcutaneous injection at doses of 5 mg, 10 mg, or 15 mg, with dose-dependent efficacy 4.